GLP-1 Medications and Cardiovascular Health: What the Research Shows

If you have been researching GLP-1 medications for weight management, you have likely come across headlines about heart health benefits. In 2023, a landmark clinical trial found that semaglutide reduced major cardiovascular events by 20% in people with obesity and existing heart disease (see our [SELECT trial deep dive](/resources/glp1-medications-cardiovascular-health-select-trial)). That finding made news well beyond the usual medical journals.

But what does the cardiovascular research on GLP-1 medications actually say? What have the trials measured, who was enrolled, and how should someone considering treatment think about this evidence?

This article answers those questions directly. It covers the clinical trial data, the biological mechanisms behind the cardiovascular effects, and the important context that anyone evaluating GLP-1 medications should understand.

*[Compounded semaglutide](/resources/compounded-semaglutide-what-it-is) and [compounded tirzepatide](/resources/compounded-tirzepatide-guide) are not FDA-approved medications. The cardiovascular outcome studies described in this article were conducted using FDA-approved branded medications. This article is for educational purposes only and does not constitute medical advice. Speak with a licensed healthcare provider before starting any new medication. For a comparison of semaglutide and tirzepatide options, see [Semaglutide vs. Tirzepatide for Weight Loss](/resources/semaglutide-vs-tirzepatide-weight-loss).*

---

Why Researchers Started Looking at GLP-1 Medications and Heart Health

GLP-1 receptor agonists were originally developed to manage blood sugar in people with type 2 diabetes. But researchers noticed something early on: patients using these medications seemed to have fewer cardiovascular events than expected. That observation prompted the large cardiovascular outcome trials that now form the backbone of what we know about GLP-1 medications and heart health.

Cardiovascular disease is the leading cause of death globally and is closely linked to obesity, type 2 diabetes, high blood pressure, and chronic inflammation. All of these conditions overlap in ways that make it difficult to separate cause and effect. GLP-1 medications act on several of these factors at once, which is one reason the cardiovascular signal stood out early.

---

How GLP-1 Medications May Affect the Heart

GLP-1 receptors are not limited to the gut and pancreas. Research has confirmed their presence in cardiac tissue, blood vessels, and the brainstem nuclei that regulate autonomic function. This distribution means GLP-1 medications may affect cardiovascular physiology through both indirect and direct mechanisms.

Indirect effects (via weight and metabolic improvement):

Weight loss alone has meaningful cardiovascular benefits. Reducing body weight by 5 to 10 percent lowers blood pressure, reduces triglycerides, improves insulin sensitivity, and decreases the mechanical load on the heart. Since GLP-1 medications produce significant weight loss in most people who take them, some of the cardiovascular benefit observed in trials is likely explained by weight reduction.

Direct metabolic effects:

Blood sugar control matters for heart health independent of weight. Chronically elevated blood glucose damages blood vessel walls, promotes atherosclerosis, and increases clotting risk. GLP-1 medications lower post-meal blood sugar spikes and improve overall glycemic control, which may reduce this vascular damage over time.

Direct effects on blood pressure:

Multiple studies have found modest but consistent reductions in systolic blood pressure (typically 2 to 5 mmHg) in people taking GLP-1 medications, even after accounting for weight loss. The mechanism is not fully understood but may involve sodium excretion via the kidneys and reductions in sympathetic nervous system activity.

Anti-inflammatory and anti-atherosclerotic effects:

GLP-1 receptors are expressed on macrophages and endothelial cells, the cell types involved in the formation and progression of arterial plaques. Some research suggests GLP-1 activity may reduce arterial inflammation and plaque instability, though this remains an area of active investigation. A 2025 review in Biomolecules examined GLP-1 receptor agonist roles across the spectrum of heart failure presentations, noting both the weight-loss-mediated and potential direct cardiac mechanisms ([PMID: 41301492](https://pubmed.ncbi.nlm.nih.gov/41301492/)).

---

What the Major Clinical Trials Found

The cardiovascular effects of GLP-1 medications have been tested in some of the largest randomized controlled trials in modern medicine. Here is what those trials found.

SUSTAIN-6: Semaglutide in Type 2 Diabetes (2016)

The SUSTAIN-6 trial enrolled 3,297 adults with type 2 diabetes who were at high cardiovascular risk. Participants were randomized to once-weekly injectable semaglutide or placebo for 104 weeks.

The trial found a 26% reduction in the risk of major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, in the semaglutide group. The reduction was driven primarily by fewer non-fatal strokes.

This trial established that semaglutide was cardiovascularly safe in people with type 2 diabetes and high CV risk, and suggested possible benefit (Marso SP et al., N Engl J Med. 2016, [PMID: 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186/)).

*SUSTAIN-6 enrolled people with type 2 diabetes using FDA-approved semaglutide doses studied in the context of diabetes management.*

LEADER: Liraglutide in Type 2 Diabetes (2016)

The LEADER trial (9,340 participants) evaluated liraglutide, a different GLP-1 receptor agonist in the same drug class, versus placebo in adults with type 2 diabetes at high cardiovascular risk.

Liraglutide reduced MACE by 13% compared to placebo over a median follow-up of 3.8 years. There were also significant reductions in cardiovascular death specifically (Marso SP et al., N Engl J Med. 2016, [PMID: 27295427](https://pubmed.ncbi.nlm.nih.gov/27295427/)).

LEADER established the first cardiovascular benefit signal for the GLP-1 class in a major randomized trial, reinforcing that the effect might reflect class-level rather than drug-specific properties.

*LEADER was conducted using FDA-approved liraglutide (brand name Victoza) at doses approved for type 2 diabetes management.*

<Image src="/images/articles/semaglutide-blood-pressure-hero.jpg" alt="Physician reviewing cardiovascular health data with a patient, illustrating the clinical assessment that precedes any GLP-1 medication prescription" className="my-8 rounded-xl w-full object-cover" />

SELECT: Semaglutide in Obesity Without Diabetes (2023)

The SELECT trial is the most significant cardiovascular study on semaglutide for a general weight management audience. It enrolled 17,604 adults with overweight or obesity (BMI of 27 or higher) and established cardiovascular disease, but without type 2 diabetes.

This distinction matters: SELECT tested whether semaglutide could reduce cardiovascular events in people whose primary condition was excess weight, not blood sugar dysregulation.

The results were striking. Semaglutide 2.4 mg once weekly reduced the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo over a mean follow-up of 39.8 months. This reduction in risk held across subgroups and was statistically significant (Lincoff AM et al., N Engl J Med. 2023, [PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)).

SELECT demonstrated that the cardiovascular benefit of semaglutide extended beyond people with type 2 diabetes to those with obesity and established heart disease.

*SELECT was conducted using FDA-approved semaglutide 2.4 mg (brand name Wegovy). The compounded semaglutide available through telehealth programs like Prescriva is not FDA-approved and has not been evaluated in cardiovascular outcome trials.*

STEP-HFpEF: Semaglutide in Heart Failure with Preserved Ejection Fraction (2024)

Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure increasingly linked to obesity. The heart muscle is stiff rather than weakened, and weight-related inflammation appears to be a significant driver.

The STEP-HFpEF trial randomized 529 adults with obesity-related HFpEF to semaglutide 2.4 mg or placebo for 52 weeks. At the end of the trial, participants on semaglutide showed greater reductions in symptoms, physical limitations, and body weight compared to placebo. The semaglutide group also had lower levels of inflammatory markers and improved exercise capacity (Kosiborod MN et al., 2024, [PMID: 39222642](https://pubmed.ncbi.nlm.nih.gov/39222642/)).

This trial extended the cardiovascular research into a specific condition where obesity drives the disease process, suggesting that weight loss through GLP-1 therapy may benefit a population with a particularly challenging form of heart disease.

---

Important Context: What These Trials Do and Do Not Tell Us

Reading cardiovascular outcome data requires some nuance.

These trials used FDA-approved branded medications. SUSTAIN-6, LEADER, SELECT, and STEP-HFpEF all used pharmaceutical-grade GLP-1 medications manufactured by Novo Nordisk or AstraZeneca, at doses approved by the FDA. The results cannot be assumed to apply to compounded semaglutide or compounded tirzepatide, which are prepared by 503A compounding pharmacies and are not FDA-approved.

Most trials enrolled high-risk populations. SELECT included people with existing cardiovascular disease. SUSTAIN-6 and LEADER enrolled people with type 2 diabetes at high CV risk. The average person considering a GLP-1 medication for weight management may have a very different baseline cardiovascular risk profile. The absolute risk reduction in a lower-risk population may be smaller than what these trials reported.

Weight loss has its own cardiovascular benefits. It is not possible to fully separate the cardiovascular effects of GLP-1 medications from the effects of weight loss itself. Some of what the trials measured is almost certainly driven by weight reduction rather than a unique pharmacological property of the drug.

Long-term data in healthy populations is limited. Most of the large trials ran for two to three years. What happens to cardiovascular risk over five or ten years of continuous GLP-1 use is still being studied.

---

Side Effects That Affect Cardiovascular Patients

GLP-1 medications have a well-characterized side effect profile. For people with cardiovascular disease or high CV risk, a few specific points are worth noting.

Nausea and vomiting: The most common side effects, especially during dose escalation, can cause fluid and electrolyte shifts. For people on certain heart medications (diuretics, ACE inhibitors), this may warrant monitoring.

Heart rate increase: Some GLP-1 medications are associated with modest increases in resting heart rate of 1 to 3 beats per minute. The clinical significance of this is debated, but it is a documented effect.

Hypoglycemia risk: GLP-1 medications alone have a very low risk of causing low blood sugar. But people also using insulin or sulfonylureas face a higher combined risk, which matters for overall cardiac safety.

Gallbladder events: Rapid weight loss of any kind can increase gallstone risk. GLP-1 trials have noted a small increase in gallbladder-related events, a finding worth discussing with a healthcare provider who knows your full history.

A 2025 comprehensive review of GLP-1 receptor agonist effects in heart failure summarized both the therapeutic potential and the monitoring considerations relevant to people with existing cardiac conditions, noting that patient selection and individualized medical oversight are critical (Crispino SP et al., Biomolecules. 2025, [PMID: 41301492](https://pubmed.ncbi.nlm.nih.gov/41301492/)).

---

What This Means if You Are Considering GLP-1 Treatment

The cardiovascular data on FDA-approved GLP-1 medications is genuinely compelling. It is also specific. These studies enrolled people with existing heart disease or type 2 diabetes. The results do not mean that every person taking a GLP-1 medication for weight loss will experience a 20% reduction in cardiovascular events.

What the research does suggest is that the GLP-1 drug class acts on multiple cardiovascular risk factors simultaneously: weight, blood pressure, blood sugar, and potentially inflammation. For people who carry elevated cardiovascular risk alongside excess weight, this overlap is clinically meaningful.

If cardiovascular health is a concern for you, the most useful step is an honest conversation with a licensed healthcare provider. A provider can assess your actual risk level, review any cardiac history, and help you understand how a medically supervised weight management program, including potential GLP-1 medication, fits within your overall care plan.

---

Disclaimer

Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Do not use this article as a substitute for professional medical consultation.

Compounding Disclaimer: Compounded semaglutide and tirzepatide available through Prescriva are not FDA-approved. They are prepared by licensed 503A compounding pharmacies based on individual patient prescriptions. Compounded medications have not been evaluated in cardiovascular outcome trials. The clinical trial results described in this article apply to FDA-approved branded medications only.

Results Disclaimer: Individual results vary. Weight management outcomes depend on many factors including diet, physical activity, genetics, and individual health history.

Provider Disclaimer: All medications prescribed through Prescriva require evaluation by a licensed healthcare provider. Prescriva is a management services organization (MSO) and does not practice medicine.

Brand Disclaimer: Blue Oak Services LLC dba Prescriva is not affiliated with or endorsed by Novo Nordisk (manufacturer of Ozempic/Wegovy) or Eli Lilly (manufacturer of Mounjaro/Zepbound).

---

Sources

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 2016;375(19):1834-1844. [PMID: 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186/)

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2016;375(4):311-322. [PMID: 27295427](https://pubmed.ncbi.nlm.nih.gov/27295427/)

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24). [PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)

1. Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction. *Eur Heart J.* 2024. [PMID: 39222642](https://pubmed.ncbi.nlm.nih.gov/39222642/)

1. Crispino SP, Nusca A, Ferro A, et al. Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure. *Biomolecules.* 2025;15(11). [PMID: 41301492](https://pubmed.ncbi.nlm.nih.gov/41301492/)